Cargando…
Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches
Juvenile idiopathic arthritis (JIA) is the most common paediatric rheumatological disorder and is classified by subtype according to International League of Associations for Rheumatology criteria. Depending on the number of joints affected, presence of extra-articular manifestations, systemic sympto...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383464/ https://www.ncbi.nlm.nih.gov/pubmed/34425842 http://dx.doi.org/10.1186/s12969-021-00629-8 |
_version_ | 1783741743990046720 |
---|---|
author | Zaripova, Lina N. Midgley, Angela Christmas, Stephen E. Beresford, Michael W. Baildam, Eileen M. Oldershaw, Rachel A. |
author_facet | Zaripova, Lina N. Midgley, Angela Christmas, Stephen E. Beresford, Michael W. Baildam, Eileen M. Oldershaw, Rachel A. |
author_sort | Zaripova, Lina N. |
collection | PubMed |
description | Juvenile idiopathic arthritis (JIA) is the most common paediatric rheumatological disorder and is classified by subtype according to International League of Associations for Rheumatology criteria. Depending on the number of joints affected, presence of extra-articular manifestations, systemic symptoms, serology and genetic factors, JIA is divided into oligoarticular, polyarticular, systemic, psoriatic, enthesitis-related and undifferentiated arthritis. This review provides an overview of advances in understanding of JIA pathogenesis focusing on aetiology, histopathology, immunological changes associated with disease activity, and best treatment options. Greater understanding of JIA as a collective of complex inflammatory diseases is discussed within the context of therapeutic interventions, including traditional non-biologic and up-to-date biologic disease-modifying anti-rheumatic drugs. Whilst the advent of advanced therapeutics has improved clinical outcomes, a considerable number of patients remain unresponsive to treatment, emphasising the need for further understanding of disease progression and remission to support stratification of patients to treatment pathways. |
format | Online Article Text |
id | pubmed-8383464 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-83834642021-08-25 Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches Zaripova, Lina N. Midgley, Angela Christmas, Stephen E. Beresford, Michael W. Baildam, Eileen M. Oldershaw, Rachel A. Pediatr Rheumatol Online J Review Juvenile idiopathic arthritis (JIA) is the most common paediatric rheumatological disorder and is classified by subtype according to International League of Associations for Rheumatology criteria. Depending on the number of joints affected, presence of extra-articular manifestations, systemic symptoms, serology and genetic factors, JIA is divided into oligoarticular, polyarticular, systemic, psoriatic, enthesitis-related and undifferentiated arthritis. This review provides an overview of advances in understanding of JIA pathogenesis focusing on aetiology, histopathology, immunological changes associated with disease activity, and best treatment options. Greater understanding of JIA as a collective of complex inflammatory diseases is discussed within the context of therapeutic interventions, including traditional non-biologic and up-to-date biologic disease-modifying anti-rheumatic drugs. Whilst the advent of advanced therapeutics has improved clinical outcomes, a considerable number of patients remain unresponsive to treatment, emphasising the need for further understanding of disease progression and remission to support stratification of patients to treatment pathways. BioMed Central 2021-08-23 /pmc/articles/PMC8383464/ /pubmed/34425842 http://dx.doi.org/10.1186/s12969-021-00629-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Zaripova, Lina N. Midgley, Angela Christmas, Stephen E. Beresford, Michael W. Baildam, Eileen M. Oldershaw, Rachel A. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches |
title | Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches |
title_full | Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches |
title_fullStr | Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches |
title_full_unstemmed | Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches |
title_short | Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches |
title_sort | juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383464/ https://www.ncbi.nlm.nih.gov/pubmed/34425842 http://dx.doi.org/10.1186/s12969-021-00629-8 |
work_keys_str_mv | AT zaripovalinan juvenileidiopathicarthritisfromaetiopathogenesistotherapeuticapproaches AT midgleyangela juvenileidiopathicarthritisfromaetiopathogenesistotherapeuticapproaches AT christmasstephene juvenileidiopathicarthritisfromaetiopathogenesistotherapeuticapproaches AT beresfordmichaelw juvenileidiopathicarthritisfromaetiopathogenesistotherapeuticapproaches AT baildameileenm juvenileidiopathicarthritisfromaetiopathogenesistotherapeuticapproaches AT oldershawrachela juvenileidiopathicarthritisfromaetiopathogenesistotherapeuticapproaches |